Plasma markers for identifying patients with metastatic melanoma

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2417-2425

  Kluger, Harriet M ^a   Hoyt, Kathleen ^b   Bacchiocchi, Antonella ^b   Mayer, Tina ^a   Kirsch, Jonathan ^b   Kluger, Yuval ^b   Sznol, Mario ^a   Ariyan, Stephan ^b   Molinaro, Annette ^c   Halaban, Ruth ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE; GLYCOPROTEIN; GROWTH DIFFERENTIATION FACTOR 15; INTERCELLULAR ADHESION MOLECULE 1; MELANOMA INHIBITORY ACTIVITY; OSTEOPONTIN; PROTEIN S100B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, CD; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 79954610158     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2402     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Ak I, Stokkel MP, Bergman W, Pauwels EK. Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur J Nucl Med 2000;27:447-58. (Pubitemid 30225008)
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
4. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007;17:393-9. (Pubitemid 350084995)
5. Ho Shon IA, Chung DK, Saw RP, Thompson JF. Imaging in cutaneous melanoma. Nucl Med Commun 2008;29:847-76.
6. Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002;55:46-54. (Pubitemid 34071906)
7. Dummer R, Hauschild A, Jost L. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2008;19 Suppl 2: ii86-8.
8. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008;95:1401-7.
9. Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hèdelin G, et al. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol 2008;144:629-36. (Pubitemid 351724423)
10. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignantmelanoma. Cancer 1999;86:2252-8. (Pubitemid 30010365)
11. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009;45:1407-14.
12. Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 2007;156:653-8. (Pubitemid 46452353)
13. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009;27:38-44.
14. Tung MC, Tsai CS, Tung JN, Tsao TY, Chen HC, Yeh KT, et al. Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1570-7.
15. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and regression. London: Chapman and Hall/CRC, 2001.
16. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 2004;165:1781-7. (Pubitemid 39435175)
17. Hoskins MH, Dong C. Kinetics analysis of binding between melanoma cells and neutrophils. Mol Cell Biomech 2006;3:79-87. (Pubitemid 44794894)
18. Metge BJ, Liu S, Riker AI, Fodstad O, Samant RS, Shevde LA. Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology 2010;78:75-86.
19. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 2008;112:144-50.
20. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009;15:6939-46.
21. Perrotta R, Bevelacqua Y, Malaguarnera G, Paladina I, Giordano M, Malaguarnera M. Serum markers of cutaneous melanoma. Front Biosci 2010;2:1115-22.
22. Yamashita T, Yoneta A, Hida T. Macrophage inhibitory cytokine-1: a new player in melanoma development. J Invest Dermatol 2009;129:262-4.
23. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 2009;129:383-91.
24. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and-2 in patients with malignant melanoma. J Dermatol 2008;35:206-14. (Pubitemid 351561711)
25. Mühlbauer M, Langenbach N, Stolz W, Hein R, Landthaler M, Buettner R, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res 1999;5:1099-105. (Pubitemid 29233225)
26. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007;27:1897-900. (Pubitemid 46954694)
27. Yamada M, Yanaba K, Takehara K, Sato S. Clinical significance of serumlevels of soluble intercellular adhesion molecule-1 and soluble Lselectin in malignant melanoma. Arch Dermatol Res 2005;297:256-60. (Pubitemid 41712812)
28. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, et al. Prognostic utility of the 21-gene assay in hormone receptorpositive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26:4063-71.
29. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009;18:15-24.
30. Gadducci A, Fuso L, Cosio S, Landoni F, Maggino T, Perotto S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: a retrospective Italian multicentric study. Int J Gynecol Cancer 2009;19:367-74.
31. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 2008;15:239-47.
32. Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 2009;35:313-9.
33. Mosca PJ, Teicher E, Nair SP, Pockaj BA. Can surgeons improve survival in stage IV melanoma? J Surg Oncol 2008;97:462-8. (Pubitemid 351466392)
34. Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs 2005;19:247-60. (Pubitemid 41430159)
35. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009;45:1807-14.
36. Atkins MB, Long GV, Warneke CL, Carlino M, DeRose ER, Johnson MM, et al. Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): preliminary report of the PHAMOUS study. J Clin Oncol 2010;28:Suppl 15 s. Abstract 8516.